文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

抑制c-Abl激酶调控桩蛋白酪氨酸磷酸化对大鼠呼吸机相关性肺损伤的保护作用

[Regulation of paxillin tyrosine phosphorylation via inhibition of c-Abl kinase to protect ventilator induce lung injury in vivo in rats].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论大鼠在体实验显示,抑制c-Abl激酶可阻断桩蛋白Y31/Y118磷酸化、保护VE-钙黏蛋白并减轻高潮气量通气所致肺损伤。

研究将90只健康雄性SD大鼠随机分为9组(每组10只),比较保护性通气(潮气量6 mL/kg、PEEP 5 cmH2O通气1或2小时)与高潮气量通气(30 mL/kg、PEEP 0通气1或2小时)对肺组织的影响,并在高潮气量通气前1小时分别给予p42/44MAPK抑制剂UO126腹腔注射1 mg/kg或c-Abl激酶抑制剂AG957灌胃10 mL/kg预处理。结果显示高潮气量组肺损伤严重,DAD评分、肺湿/干重比、伊文思蓝含量、MPO活性及BALF中TNF-α均显著高于假手术组和保护性通气组;AG957或UO126预处理后上述指标均显著下降。作者认为抑制c-Abl激酶可阻断桩蛋白Y31/Y118磷酸化、强化VE-钙黏蛋白连接,并可能阻断Pxn-GEF-H1-p44/42MAPK信号体诱导的局部Rho信号活化及肌球蛋白轻链磷酸化。

要点

  • 高潮气量通气(30 mL/kg、PEEP 0)1或2小时的大鼠肺组织损伤严重,DAD评分、肺湿/干重比、伊文思蓝含量、MPO活性及BALF中TNF-α均显著高于假手术组和保护性通气组。
  • 高潮气量通气前1小时灌胃c-Abl激酶抑制剂AG957 10 mL/kg预处理,可使高潮气量通气2小时时肺组织p-c-Abl Y245、p-Pxn Y31、p-Pxn Y118、p-VE-cad Y658、p-p42/44MAPK Y202/Y204、p-MLC、p-MYPT Y696灰度值均显著低于高潮气量组(均P<0.05)。
  • 高潮气量通气前1小时腹腔注射p42/44MAPK抑制剂UO126 1 mg/kg预处理,可使高潮气量通气2小时时p-VE-cad Y658、p-p42/44MAPK Y202/Y204、p-MLC、p-MYPT Y696灰度值均显著低于高潮气量组(均P<0.05)。
  • 作者认为抑制c-Abl激酶可阻断桩蛋白Y31/Y118磷酸化,强化VE-钙黏蛋白连接,并可能阻断Pxn-GEF-H1-p44/42MAPK信号体诱导的局部Rho信号活化、MLC磷酸化及肌动蛋白-肌球蛋白收缩。
  • 该研究为大鼠在体实验,AG957与UO126为实验性预处理用药,结果不能直接转化为急诊/ICU临床推荐。

适用人群与场景

  • 健康雄性Sprague-Dawley(SD)大鼠90只,随机分为9组,每组10只。
  • 实验场景为在体动物机械通气模型,非急诊/ICU患者人群。

处置流程与药物剂量

  • 保护性通气组:潮气量6 mL/kg、PEEP 5 cmH2O(1 cmH2O=0.098 kPa),通气1小时或2小时(PVT 1 h、PVT 2 h组)。
  • 高潮气量通气组:潮气量30 mL/kg、PEEP 0,通气1小时或2小时(HVT 1 h、HVT 2 h组)。
  • AG957预处理组:高潮气量通气前1小时灌胃c-Abl激酶抑制剂AG957 10 mL/kg,然后行高潮气量通气1小时或2小时。
  • UO126预处理组:高潮气量通气前1小时腹腔注射p42/44MAPK抑制剂UO126 1 mg/kg,然后行高潮气量通气1小时或2小时。
  • 假手术组仅行气管切开。

研究设计与关键结果

  • 研究类型为大鼠在体实验,90只健康雄性SD大鼠随机分为9组,每组10只。
  • 假手术组与PVT 1 h、PVT 2 h组肺组织无明显病理改变,各项参数组间无显著差异。
  • HVT组肺组织损伤严重,DAD评分、肺湿/干重比、伊文思蓝含量、MPO活性及BALF中TNF-α均显著高于假手术组和PVT组。
  • AG957或UO126预处理后,上述所有参数较HVT组显著下降。
  • HVT组肺组织各蛋白磷酸化水平较假手术组和PVT组升高,尤其通气2小时时。
  • AG957预处理组通气2小时时各磷酸化蛋白灰度值均显著低于HVT组:p-c-Abl Y245 0.29±0.04 vs. 0.42±0.04,p-Pxn Y31 0.51±0.03 vs. 0.70±0.05,p-Pxn Y118 0.65±0.04 vs. 0.91±0.04,p-VE-cad Y658 0.77±0.07 vs. 1.32±0.07,p-p42/44MAPK Y202/Y204 0.38±0.06 vs. 0.61±0.03,p-MLC 0.37±0.04 vs. 0.77±0.05,p-MYPT Y696 0.54±0.05 vs. 0.87±0.06,均P<0.05。
  • UO126预处理组通气2小时时p-VE-cad Y658灰度值0.74±0.04 vs. HVT组1.32±0.07,p-p42/44MAPK Y202/Y204 0.38±0.07 vs. 0.61±0.03,p-MLC 0.37±0.04 vs. 0.77±0.05,p-MYPT Y696 0.55±0.05 vs. 0.87±0.06,均显著低于HVT组(均P<0.05)。

证据类型、等级与局限

  • 证据类型:大鼠在体实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究为大鼠在体实验,AG957与UO126为实验性预处理用药,原文未据此给出急诊/ICU临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine whether the inhibition of paxillin tyrosine residues 31 and tyrosine residues 118 (Pxn Y31 and Pxn Y118) phosphorylation via inhibition of c-Abl kinase will effectively block its downstream effector molecules vessel endothelium-cadherin (VE-cad), and whether Rho/Rho kinase activation which will induce the vascular barrier dysfunction.

METHODS: Ninety healthy male Sprague-Dawley (SD) rats were randomly divided into nine groups (each n =10). Only tracheotomy was undergone in the sham group. Groups of protective ventilation were set at a volume tidal (VT) of 6 mL/kg, a positive end-expiratory pressure (PEEP) of 5 cmH2O (1 cmH2O = 0.098 kPa) for 1 hour or 2 hours (namely group PVT 1 h and group PVT 2 h), respectively. Groups of high VT were put on mechanical ventilation (MV) at high VT 30 mL/kg, PEEP 0 for 1 hour or 2 hours (namely group HVT 1 h and group HVT 2 h), respectively. Groups UO126 and AG957 pretreatment were set on MV at HVT for 1 hour or 2 hour respectively, but they were given p42/44 mitogen-activated protein kinase (p42/44MAPK) inhibitor UO126 1 mg/kg by intraperitoneal injection or c-Abl kinase inhibitor AG957 10 mL/kg by intragastric injection 1 hour before HVT ventilation. All the animals were sacrificed after experiments and specimens of lung tissues and bronchoalveolar lavage fluid (BALF) were harvested. Pulmonary vascular permeability was measured by Evans blue (EB). The levels of tumor necrosis factor-α (TNF-α) in BALF were measured by enzyme linked immunosorbent assay (ELISA). Then the change of lung tissue pathology was observed with light microscope, diffuse alveolar damage system (DAD) score and lung wet/dry ratio (W/D) were estimated. The myeloperoxidase (MPO) activity was measured by colorimetric analysis, phosphorylations of c-Abl Y245, Pxn Y31, Pxn Y118, VE-cad Y658, p42/44MAPK Y202/Y204, myosin light chain (MLC) and myosin-associated phosphatasetype Y696 (MYPT Y696) were determined by Western Blot.

RESULTS: (1)There were no obvious pathological changes in the lung tissue in the sham group and PVT 1 h or 2 h group, and also there were no significant differences in all the parameters between above groups. However, the injury in lung tissue was severe in the HVT groups. In addition, DAD score, lung W/D ratio, EB content, the activity of MPO, and TNF-α in BALF in HVT groups were significantly higher than those in sham group and PVT groups. After pretreatment with AG957 or UO126, all the parameters were significantly decreased as compared with those of groups HVT. (2) The levels of phosphorylation of the proteins in lung tissue in HVT groups were increased as compared with those of group sham and groups PVT, especially at 2 hours of MV. However, compared with groups HVT, the level of p-VE-cad Y658 in lung tissue decreased significantly in group AG957 and group UO126 at 2 hours after HVT. However, the levels of all phosphorylated proteins at 2 hours were significantly lowered in the AG957 group compared with those of the HVT group [p-c-Abl Y245 (gray value): 0.29±0.04 vs. 0.42±0.04, p-Pxn Y31 (gray value): 0.51±0.03 vs. 0.70±0.05, p-Pxn Y118 (gray value): 0.65±0.04 vs. 0.91±0.04, p-VE-cad Y658 (gray value): 0.77±0.07 vs. 1.32±0.07, p-p42/44MAPK Y202/Y204 (gray value): 0.38±0.06 vs. 0.61±0.03, p-MLC (gray value): 0.37±0.04 vs. 0.77±0.05, p-MYPT Y696 (gray value): 0.54±0.05 vs. 0.87±0.06, all P < 0.05]. After pretreatment with UO126, the phosphorylation level of VE-cad in lung tissue at 2 hours was significantly lower than that of HVT group (gray value: 0.74±0.04 vs. 1.32±0.07), and the phosphorylation levels of p42/44MAPK and its downstream effector molecules MLC and MYPT Y696 were also significantly decreased [p-p42/44MAPK Y202/Y204 (gray value): 0.38±0.07 vs. 0.61±0.03, p-MLC (gray value): 0.37±0.04 vs. 0.77±0.05, p-MYPT Y696 (gray value): 0.55±0.05 vs. 0.87±0.06, all P < 0.05].

CONCLUSIONS: Pxn Y31 and Pxn Y118 phosphorylation could be blocked by inhibition of c-Abl kinase, which could strengthen VE-cad at attachment junction and might block formation of Pxn-guanine nucleotide-exchange factor H1 (GEF-H1)-p44/42MAPK signalosome which induce activation local Rho signaling, lead to activation of MLC phosphorylation, actomyosin contraction, and increase endothelial permeability.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhong R, Xiao J, Dai C, et al. [Regulation of paxillin tyrosine phosphorylation via inhibition of c-Abl kinase to protect ventilator induce lung injury in vivo in rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28743335. doi:10.3760/cma.j.issn.2095-4352.2017.07.005

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。